PDGFRA and cancer: As previously reported [18,19,20,21,22,23], inhibiting PDGFRα (overexpressed and/or abnormally activated) can reduce many types of cancer, including prostate, ovarian, breast, pancreatic, and liver cancers, by inactivating downstream signaling pathways that regulate cell proliferation, migration, and angiogenesis [24,25,26].